Validation of a Next-Generation Sequencing Assay for Clinical Molecular OncologyCatherine E. Cottrell, John D. Pfeifer, Christina M. Lockwood et al.|Journal of Molecular Diagnostics|2013Cited by 184
A Phase II Trial of Neoadjuvant MK-2206, an AKT Inhibitor, with Anastrozole in Clinical Stage II or III <i>PIK3CA</i> -Mutant ER-Positive and HER2-Negative Breast CancerX. Cynthia, Matthew J. Ellis, Vera J. Suman et al.|Clinical Cancer Research|2017Cited by 74
Detection of Gene Rearrangements in Targeted Clinical Next-Generation SequencingHaley Abel, Eric J. Duncavage, Hussam Al‐Kateb et al.|Journal of Molecular Diagnostics|2014Cited by 70